Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People with a general health status that allows them to carry out daily activities, either fully or with some limitations (confirm with trial site what level of functioning is required)
- People who have been diagnosed with a specific type of cancer — confirmed by lab testing — that started in the ovaries, fallopian tubes, or the lining of the abdomen, at a certain stage of advancement, and who have had some response (but not enough) to three cycles of a standard chemotherapy combination, meaning full surgical removal of the tumour is not yet possible
- People whose blood cell counts meet certain minimum levels — enough white blood cells, red blood cells, and platelets — as confirmed by blood tests
- People whose kidneys and liver are functioning well enough, as confirmed by blood tests
- People who do not have serious unstable health conditions, such as a recent heart attack, uncontrolled blood pressure, or severe infections, among others (confirm with trial site for the full list)
- People who have given written agreement to take part before any trial procedures begin
- People who are covered by a national health insurance system
Who may not be able to join:
- People whose cancer has spread to areas outside the abdomen in a way that would prevent potentially curative surgery
- People who have signs of bowel blockage, bowel lesions at risk of tearing, or inflammatory bowel disease
- People who cannot receive intravenous carboplatin-paclitaxel chemotherapy, including those with a known severe allergic reaction to paclitaxel
- People who cannot undergo the PIPAC procedure (a type of treatment delivered directly into the abdomen), including those with a known allergy to cisplatin or similar drugs, doxorubicin or similar drugs, or those with certain heart conditions
- People with a known allergy to sodium thiosulfate, sulfites, or related substances
- People who have received a live vaccine within 3 months before the start of the trial, or who plan to receive one during the trial
- People who are pregnant or breastfeeding
- People who are under legal guardianship or any form of legal protection, or who have had their liberty restricted
- People who are currently participating in another clinical trial that has an overlapping exclusion period, or one that could affect the results of this study
- People who, for geographical, personal, or psychological reasons, would be unable to attend the required follow-up visits
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Justine ARQUILLIERE, MD, Hospices Civils de Lyon
Phone: 04 78 86 23 71
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.